Amgen Inc. (AMGN)

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amgen (AMGN) concluded the recent trading session at $318.65, signifying a +0.47% move from its prior day's close.

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

Equity markets can move every which way from one day to the next. The more we extend our horizon, the more likely it is that stocks will provide juicy returns.

The latest trading day saw Amgen (AMGN) settling at $317.17, representing a +1.1% change from its previous close.

New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with generalized myasthenia gravis.

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amgen (AMGN). But which of these two companies is the best option f...

Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual mechanism a...

Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.